• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    11/14/24 7:53:01 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDMO alert in real time by email
    SC 13G/A 1 p24-3265sc13ga.htm
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G/A
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
     

    Avid Bioservices, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)
     

    05368M106

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 05368M10613G/APage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,285,594

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,285,594

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,285,594

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.7%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 05368M10613G/APage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    4,285,594

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    4,285,594

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,285,594

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.7%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 05368M10613G/APage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Europe (London) LLP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United Kingdom

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    997,046

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    997,046

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    997,046

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.6%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

    CUSIP No. 05368M10613G/APage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    5,282,640

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    5,282,640

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,282,640

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    8.3%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 05368M10613G/APage 6 of 8 Pages

     

     

    Item 1(a). Name of Issuer.
      Avid Bioservices, Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      14191 Myford Road, Tustin, California 92780.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to shares of common stock, par value $0.001 per share (“Shares”), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by Point72 Associates; (iii) Point72 Europe (London) LLP (“Point72 Europe (London)”) with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Point72 Europe (London).
       
      Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited and Point72 Asia (Singapore) Pte. Ltd. are advisors under common control with Point72 Asset Management, and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
       
      Point72 Asset Management, Point72 Capital Advisors Inc, Point72 Europe (London), and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Point72 Europe (London) is 8 St. James’s Square, London, United Kingdom, SW1Y 4JU.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation.  Point72 Europe (London) is a limited liability partnership incorporated in England and Wales. Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.001 per share.

     

    Item 2(e). CUSIP Number.
      05368M106

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    CUSIP No. 05368M10613G/APage 7 of 8 Pages

     

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on September 30, 2024.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., Point72 Europe (London), and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Point72 Europe (London) maintains investment and voting power with respect to the securities held by an investment fund it manages.  Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Point72 Europe (London).   The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [  ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 05368M10613G/APage 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      POINT72 EUROPE (LONDON) LLP
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title: Authorized Person
       
       
      STEVEN A. COHEN
       
      By:  /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

     

    Get the next $CDMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CDMO

    DatePrice TargetRatingAnalyst
    9/28/2023Mkt Perform
    William Blair
    3/14/2023$20.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/9/2022$31.00 → $28.00Overweight
    Stephens & Co.
    12/8/2021$29.00 → $35.00Buy
    Craig-Hallum
    12/8/2021$27.00 → $32.00Outperform
    RBC Capital
    12/8/2021Overweight → Sector Weight
    Keybanc
    6/30/2021$21.00 → $29.00Buy
    Craig-Hallum
    6/30/2021$21.00 → $27.00Outperform
    RBC Capital
    More analyst ratings

    $CDMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      1/10/24 7:56:02 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      12/18/23 7:31:12 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      9/22/23 12:51:46 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Financials

    Live finance-specific insights

    See more
    • Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024

      TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024. Highlights from the Quarter Ended October 31, 2024: "We delivered solid results in a competitive environment, with increased revenues and backlog offset by increased costs," stated Nick Green, president and CEO of Avid Bioservices. "We are pleased to reach the separately announced agre

      12/10/24 4:05:23 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

      -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:

      9/9/24 4:05:31 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

      TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please

      9/3/24 4:05:20 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Avid Bioservices

      William Blair initiated coverage of Avid Bioservices with a rating of Mkt Perform

      9/28/23 8:08:44 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Avid Bioservices from Sector Weight to Overweight and set a new price target of $20.00

      3/14/23 7:17:41 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

      Stephens & Co. reiterated coverage of Avid Bioservices with a rating of Overweight and set a new price target of $28.00 from $31.00 previously

      3/9/22 6:57:34 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

      TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers. The reimagined Avid website captures the company's elevated brand throu

      2/10/25 8:05:59 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

      TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the "Notice") to holders of its 7.00% Convertible Senior Notes due 2029 (the "Notes"), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the "Indenture"), by and between the Company and U.S. Bank Trust Company, National Association ("U.S. Bank"), as trustee, governing the Notes that, in connection with the closing of the transa

      2/5/25 10:45:00 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

      Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners ("Ampersand"), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices

      2/5/25 9:55:00 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Avid Bioservices Inc.

      SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

      12/13/24 10:53:25 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

      SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

      11/14/24 7:53:01 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

      SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

      11/12/24 4:15:31 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Avid Bioservices Inc.

      15-12G - Avid Bioservices, Inc. (0000704562) (Filer)

      2/18/25 6:07:47 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Avid Bioservices Inc.

      S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

      2/5/25 5:13:38 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Avid Bioservices Inc.

      S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

      2/5/25 5:13:36 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      2/7/25 7:40:25 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      2/7/25 7:40:10 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Avid Bioservices, Inc. (0000704562) (Issuer)

      2/7/25 7:39:57 PM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CDMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

      12/1/23 6:16:00 PM ET
      $ALK
      $ALKS
      $AWI
      $BLDR
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

      DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

      5/3/23 4:30:00 PM ET
      $CDMO
      $STE
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Avid Bioservices Appoints Oksana Lukash as Vice President, People

      TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year

      11/16/22 8:05:00 AM ET
      $CDMO
      Biotechnology: Pharmaceutical Preparations
      Health Care